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MDCTAbstract Purpose: To evaluate the effectiveness of percutaneous ultrasonographic guided
radiofrequency thermal ablation in the management of hepatocellular carcinoma.
Patients and methods: This study included 100 patients presented with HCC showed 110 lesions, 91
lesions in the right lobe and 19 lesions in the left lobe. 86 were males (86%) and 14 were females
(14%). All patients were subjected to laboratory investigations and imaging assessment including
CT chest, bone scan, abdominal US and Triphasic Multislice Computed Tomography (MSCT) of
the abdomen. The Radio Frequency Ablation (RFA) systems used were Radiofrequency Interstitial
Thermal Ablation (RITA) System and RF 3000 monopolar system.
Results: Good ablation was achieved in 92 of 100 (92%) patients treated by RFA after the ﬁrst session,
incomplete necrosis found in 8 of 100 patients (8%). Local recurrence after RFA treatment occurred in 36
of 100 patients (36%). Local recurrence occurred after one month in one of 36 patients (2.8%), after
3 months in 24 of 36 patients (66.7%), after 6 months in 8 of 36 patients (22.2%), after 9 months in 2
of 36patients (5.5%)andafter 12 months in1of 36patients (2.8%).At the endof theﬁrst year, the survival
of the patients was (97%), at the end of the second year, the survival of the patients was (71.0%).
Conclusion: Radiofrequency thermal ablation is a simple, effective and less expensive technique with a
low morbidity compared with surgical treatment. Radiofrequency thermal ablation can produce signiﬁ-
cant long-term survival rates and excellent local control for cirrhotic patientswith early stage, unresectable
HCC.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.
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Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer in the world (564,000 cases per year) and the third most
frequent cause of cancer-related deaths (1).
Surgical resection is considered to be potentially curative
therapy. However, only about 20% of HCC patients are
resectable; the remainders are irresectable because of multifo-
cal tumors, advanced tumors, tumor location precluding
complete resection, or poor hepatic functional reserve (2).
Different locoregional therapies have been developed for
irresectable liver tumors with an attempt to achieve local tu-
mor control. These include transarterial chemoembolization
(TACE), percutaneous ethanol injection (PEI), and various
thermal ablation therapies such as cryotherapy, interstitial
laser therapy, microwave coagulation and radiofrequency
ablation (3,4).
For irresectable tumors, RFA seems to be the most effec-
tive treatment among other locoregional therapies. The main
advantages of RFA include low morbidity and mortality rates,
effective tumor ablation and preservation of maximal normal
liver parenchyma (5). However, despite the high complete
necrosis rate of RFA, early tumor recurrence within one year,
either local tumor recurrence or new tumor formation, remains
a signiﬁcant problem (6).
Radiofrequency ablation (RFA), also known as ‘‘radiofre-
quency thermal ablation,’’ is a recently developed thermoabla-
tive technique. It induces temperature changes by using
high-frequency alternating current applied via electrodes
placed within the tissue to generate areas of coagulative
necrosis and tissue desiccation. Radiofrequency ablations can
be applied percutaneously, laparoscopically, or at open surgery
(7).
1.1. Aim of the work
The aim of this study was to evaluate the effectiveness of per-
cutaneous ultrasonographic guided radiofrequency thermal
ablation in the management of HCC.2. Patients and methods
2.1. Population
Between March 2011 and April 2013, 100 patients had HCC
showed 110 lesions, 91 lesions in the right lobe and 19 lesions
in the left lobe included in this study, 86 males (86%), and 14
females (14%). Their age ranged from 35 to 73 years, with a
mean age of 57.45 years. The patients referred to the Radiodi-
agnosis Department, Tanta University and National Liver
Institute, Menufya University and planned to be treated with
RFA. Exclusion criteria were based on patients with eligibility
for surgical resection, extra hepatic metastases, diffuse inﬁltra-
tive type HCC, vascular or bile duct invasion, severe coagula-
tion disorder as prothrombin concentration less than 50% and
platelet count less than 70/000 cmm3 and uncountable ascites,
lesion more than 5 cm or more than 3 lesions. The study was
approved by the ethics committee of our institution. Written
informed consent from the patients was obtained prior to each
examination.2.2. Methods
I. Pre-RFA Procedure Assessment
1. Thorough history taking.
2. Clinical examination.
3. Laboratory investigations
4. Imaging assessment:
The aim of pre RFA radiological assessment was to evalu-
ate intrahepatic disease and to exclude extrahepatic extension.
4.1. High resolution CT chest: Preprocedural CT chest was
routinely done.
4.2. Abdominal US with color Doppler study:
Using electronically focused curvilinear transducers rang-
ing in frequency from 2.5 to 5.0 MHz combined with a color
Doppler system (Sonoline Sienna, Siemens Medical Systems,
USA). The size, multiplicity, location and echopattern of the
hepatocellular carcinomas were assessed with Couinaud
nomenclature as well as conﬁrming the patency of portal and
hepatic veins, bile duct invasion, LN enlargement and ascites.
4.3. Triphasic CT examination:
Triphasic Multislice Computed Tomography (MSCT)
study of the abdomen was performed on a spiral CT scanner
(Somatom plus 2; Siemens, Erlangen, Germany). All patients
initially underwent a baseline pre-contrast scan; followed by
three scans performed at 20, 60, and 180 s after intravenous
administration of 100 ml of contrast medium (Ultravist 370,
Schering, Berlin, Germany) at a rate of 3 ml/s, to arterial, por-
tal/venous and equilibrium phases, respectively. The size, mul-
tiplicity and location of the hepatocellular carcinomas were
assessed with Couinaud nomenclature as well as that the dis-
ease conﬁned to the liver, without evidence of vascular inva-
sion or extra-hepatic metastases or biliary dilatation.
II. Radio Frequency Ablation (RFA) systems used:
A. Radiofrequency Interstitial Thermal Ablation (RITA)
System:
Ablation was done by 1500 generator (Starburst XL, RITA
Medical System) with a power of up to 150 W and 9 electrode
prongs, 5-cm thermal ablation catheter which is 14 or 15G and
12, 15, or 25 cm in length. It contains one electrode in the
center and 4 prongs having thermocouples at the tips and a
monitor that displays tissue temperature and impedance
around the tip of the needles. This system allows the ablation
of lesions that are 5 cm in diameter.
B. RF 3000 monopolar system produced by Boston
Scientiﬁc Corp. (Natick, MA, USA; formerly
Radiotherapeutics):
Ablation was done by 3000 generator with a power of up to
200 W and the LeVeen electrode is a 15 gauge, 15 cm long
insulated cannula with 1 cm shaft markers and echogenic tip
that help to guide insertion under ultrasound guidance. It
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deployed in situ perpendicular to the axis of the probe. When
these are fully extended, their diameter is 5 cm and the device
assumes an umbrella-shaped array design to help create a
complete, predictable, spherical thermal lesion.
III. Radiofrequency Ablation Technique
A. Pre-procedural work-up
The procedure was done in a special sterilized unit contain-
ing the ultrasound machine, the services of general anesthesia,
the radiofrequency system, and a mobile sterile table (for sterile
patients’ and doctors’ gowns, antiseptics, syringes, IV ﬂuid
medications, and gauze). The grounding pads, representing
the dispersive electrode, are placed on the patient’s thighs and
properly connected to the generator. The system was tested
to be sure working. The patient was prepared and draped in
the usual sterile manner, the right upper abdominal region is
adequately sterilized, and the patient is placed in either the su-
pine or the left lateral decubitus position depending on the site
of the tumor and the planned needle track. Most of our patients
were treated under local anesthesia and sedation. Local anes-
thesia was performed from the entry side on the skin to the liver
capsule along the needle track with 10 ml of 2% xylocaine. Skin
was pricked with a small sterile lancet. The patients were sub-
jected to RFA under light general intravenous anesthesia con-
sisting of a propofol infusion (deprivane, 3–6 mg/kg/h) and
fentanyl citrate IV injection (fentanyl, 1–2.5 ug/kg). The advan-
tages of the propofol are the deep level of anesthesia that can be
obtained and the short duration of action.
B. Procedural work-up
The Star Burst XL needle electrode was introduced into the
liver through the skin incision and advanced to the target area
of tumor under US guidance. The free hand technique was used
with the needle electrode parallel to the plane of the US probe.
After verifying the positioning of the needle electrode, the mul-
tiple arrays were deployed and the needle electrode was con-
nected to the RF generator. Maximum power output of the
RF generator, amount of electrode array deployment from
the trocar, and the duration of the effective time of the ablation
(time at target temperature) depend on the desired volume of
ablation. This is established at the beginning of the procedure
with the goal of destroying the visible tumor mass plus 0.05
to 1-cm safety margin of ablation all around. During treatment,
the area of tissue ablation is monitored by US to measure the
zone of increased echogenicity corresponding to the coagula-
tion of the tissues produced by the resulting nitrogen gas micro-
bubbles. At the end of the procedure, when the generator runs
off, a ‘‘cool down cycle’’ is automatically performed. After
retracting the hooks, the coagulation of the needle track is per-
formed (track ablation) at temperature above 75 C with the
aim of preventing any tumor cell dissemination. To treat larger
tumors, multiple ablations were needed to be overlapped to
build a composite thermal lesion with sufﬁcient size to kill the
entire tumor and to provide 1 cm tumor-free margin.
C. Post-procedural work-up
After the procedure, the patient referred to the ward for
overnight observation of vital data and signs of postablationsyndrome. The patient rescanned with ultrasound for 2 h after
treatment to detect any bleeding in the liver or the peritoneal
cavity. Postprocedural pain management started on need basis
by 2 g Paracetamol HCl (Perfalgan; B.M.S.) administrated
intravenously. If patient still in pain, 50 mg Pethidine adminis-
trated intramuscularly. Prophylactic antibiotics continued by
1 g Cefoperazone (Cefobid; Pﬁzer) every 12 h for two doses
administrated intravenously. Thereafter, antibiotics continued
by 500 mg Cephadroxil monohydrate (Duricef; B.M.S.) every
8 h administrated orally for 7 days. Follow-up performed
4 weeks postprocedural included:
1. Laboratory investigations
 Liver function status: ALT, AST, ALP, fractional and
total bilirubin.
 Serum protein proﬁle: serum albumin and total protein.
 Coagulation proﬁle: prothrombin time, and interna-
tional normalized ratio (INR).
 Complete blood count
 Renal function: blood urea and creatinine.
 Hepatic tumor markers: alpha fetoprotein.
2. Radiological investigations
Dynamic CT scan was done one month after completion of
the RFA therapy and several possibilities could be detected. If
there was no evidence of residual tumor, dynamic CT scan was
performed every 1 month for 3 months, then every 3 months to
detect any residual or recurrence in the ablated tumor and to
monitor for the development of new hepatic or extrahepatic
disease. Additionally, we obtain AFP levels every 1 month.
In local or distant recurrence, the patients were retreated with
RFA treatment. Also transarterial chemoembolization
(TACE) was done in some patients not ﬁt for RFA treatment
or multiplicity developed.
3. Image analysis
Adequate ablation: Deﬁned as the presence of a well-deﬁned
area of non-enhancing tissue including the treated tumor on
images obtained in both the arterial and portal phases of
enhanced CT images was considered to indicate complete
necrosis. The ablation zone was beyond the tumor borders.
The margin of the ablation zone was well-deﬁned and smooth.
No contrast enhancement was detected within or around the
tumor.
Local recurrence:Deﬁned as tumor nodules that emerged in
the same liver segment as that of the treated tumor.
Distant recurrence: Deﬁned as the appearance of new
tumors in a different hepatic segment from that of the treated
tumor. If there were local or distant recurrence, the patients
were retreated with RFA treatment. Also TACE was done in
some patients not ﬁt for RFA treatment or multiplicity devel-
oped. Supportive treatment was conducted in some cases not
suitable of RFA or TACE.
4. Statistical analysis
Data were collected, revised, veriﬁed, and then edited on
personal computer. The data were then analyzed statistically
using SPSS statistical package version 12. The following tests
were done: X=Mean Median. SD = Standard Deviation.
Table 2 Distribution of HCC focal lesions among hepatic
lobes.
Number of patients Number of lesions
No. % No. %
Right lobe 84 84 86 78.20
Left lobe 11 11 14 12.70
Bilobar 5 5 10 9.10
Total 100 100.00 110 100.00
Table 4 Showing complications after RFA in 100 HCC
patients.
Complication N %
Post RFA complications 27 27.00
RT sided pleural eﬀusion 20 20
Peritoneal hemorrhage 2 2
Liver abscess 3 3
Biliary stricture 2 2
Table 3 RFA needle used in 100 HCC patients.
RFA needle N %
LeVeen needle 4 cm (Boston scientiﬁc) 67 67
Star burst XL needle 5 cm (Rita system) 28 28
Star burst XL needle 7 cm (Rita system) 5 5
Total 100 100
Chi-Square X2 58.940
P-value <0.001*
* P< 0.05.
426 M.A. Youssef et al.T-test for independent samples. X2 = Chi-Square Test. A (P)
value of less than 0.05 was considered signiﬁcant.
5. Results
This study included 100 patients, 86 males (86%), and 14 fe-
males (14%) with male and female ratio of 6.14:1. Their age
ranged from 35 years to 73 years, with a median age of
57.45 years. There were 110 lesions, 91 lesions in the right lobe
and 19 lesions in the left lobe as shown in Tables 1 and 2. All
patients were diagnosed to have HCC and were candidate for
radiofrequency ablation.
In our study, 69 of 100 patients (69%) were treated by Star
burst XL needle 5 CM (RITA system), 24 of 100 (24%) were
treated by LeVeen needle 4CM (Boston scientiﬁc system)
and seven of 100 patients (7%) were treated by Star burst
XL needle 7 CM (RITA system) as shown in Table 3.
Twenty-seven of 100 patients (27%) developed post RFA
complications. Twenty of 27 patients (74%) developed mild
Rt sided pleural effusion due to ablation of sub-diaphragmatic
tumor, two of 27 patients (8%) developed mild peritoneal
hemorrhage, 3 of 27 patients (11%) developed liver abscess
and 2 of 27 patients (7%) developed post RFA treatment bil-
iary stricture, one of them was treated by external biliary
drainage and the other was treated by biliary stenting as shown
in Table 4.
In our study, the time and management local and distant
recurrence after RFA treatment occurred in 36 of 100 patients
(36%) as shown in Table 5 . Figs. 1–3.
In our study, the survival of the patients depends on the
severity of the liver cirrhosis, so the mean survival of Child-
Pugh Class A patients was 21.8 ± 5.29.8 m, for Child-Pugh
Class B patients was 20.6 ± 5.399 and for Child-Pugh Class
C patients was 12 ± 0.00. The survival of the patients in
relation to tumor number was 20.7 ± 5.414 m for solitary
tumors and 19.2 ± 6.195 for multiple tumors. So, the tumor
number has no signiﬁcant correlation with the survival. The
survival of the patients in relation to tumor size was
22 ± 4.560 m for tumors less than or equal to 3 cm,
20.5 ± 5.48 for tumors 3.1–4 cm, 15.4 ± 5.85 for tumors
4.1–5 cm. So, the tumor size has a signiﬁcant correlation with
the survival of the patients as shown in Table 6.
6. Discussion
Hepatocellular carcinoma (HCC) is a major health problem
worldwide, with an estimated incidence ranging between
500,000 and 1,000,000 new cases annually. It is the ﬁfth most
common cancer in the world and the third most common cause
of cancer-related deaths (8).
Hepatocellular carcinoma incidence is increasing worldwide
due to dissemination of hepatitis B and C virus infection.Table 1 Number of HCC lesions in 100 patients.
Number of patients Number of lesions
No. % No. %
Single 90 90.00 90 81.8
Two 10 10.00 20 18.2
Total 100 100.00 110 100Patients with cirrhosis are the highest at risk of developing
HCC and should undergo surveillance programmes to detect
the tumor at an early, asymptomatic stage (9).
Nowadays, HCC is diagnosed at an early stage with
increasing frequency, opening good perspectives to radical
treatment by means of liver transplantation, surgical resection,
or percutaneous ablation. Liver transplantation is considered
the best option, as it allows eliminating both tumor and cirrho-
sis at the same time, but the lack of liver donors represents a
major limitation. Therefore, surgical resection, offering a 5-
year-survival rate of over 50%, is considered the ﬁrst-choice
treatment for patients with early stage HCC, whereas percuta-
neous ablation is usually reserved to patients who are not
candidate to surgery owing to impaired liver function or
co-morbidity, or who refuse surgery (10).
In recent years, the use of percutaneous ablative therapies
such as radiofrequency (RF) ablation to treat primary and sec-
ondary liver tumors has increased as the underlying technology
has improved in its ability to achieve adequate volumes of
tumor necrosis. In situ thermal destruction of liver tumors uses
techniques that destroy tumor tissue through heating (RF
ablation, laser ablation, microwave ablation, or high-intensity
focused ultrasound) or freezing (cryotherapy). Each of these
techniques relies on controlled energy delivery to minimize
Table 5 The time and management of local and distant
recurrence in 100 HCC patients.
N %
Time of recurrence
1 Month 1 2.78
3 Months 24 66.67
6 Months 8 22.22
9 Months 2 5.56
12 Months 1 2.78
Management
RFA 11 30.56
TACE 24 66.67
Alcohol 1 2.78
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surrounding structures (11).
Radiofrequency ablation (RFA) is considered a promising
alternative to surgery. For irresectable tumors, RFA seems
to be the most effective treatment among other loco-regional
therapies. The main advantages of RFA include low morbidity  
Pre-ablation
One month post-ablation
6-monthpost-ablation 
(A)
(D)
(G)
Fig. 1 Male patient 50 year old of Child-Pugh calss A, presented wi
(primary presentation). A single session of RFA was done. (A–C) Triph
arterial phase and washout in the portovenous and delayed phases. (
revealed complete necrosis with no residual enhancing tumor. (G–I)
complete necrosis with no local or distant recurrence obtained.and mortality rates, effective tumor ablation and preservation
of maximal normal liver parenchyma (12).
In our study, RFA was used to treat 110 discrete HCC foal
lesions in 100 patients. It is noted that 90 of 100 (90%) had sin-
gle focal lesion, while 10 of 100 patients (10%) had two focal
lesions, 84 of 100 patients (84%) had right liver lobe HCC
focal lesions, 11 of 100 patients (14%) had left liver lobe focal
lesions, and 5 of 100 patients had both right and left lobe HCC
focal lesions.
This goes in agreement with Rosen and Nagorney, 1997
(13) who stated that HCC occurs most frequently in the right
hepatic lobe, either as solitary mass or as multiple nodules.
In our study, to only one of 100 patients (1%), US guided
liver biopsy was performed to conﬁrm the diagnosis due to
atypical vascular proﬁle on triphasic CT scan and alpha-feto-
protein level was less than 200 ng/ml. Poon et al. 2004 (14)
agree that in patients with typical radiological features of
HCC in combination with a diagnostic level of serum AFP,
a needle biopsy is probably not necessary before RFA.
Percutaneous approach is the least invasive route for RFA.
Patients with one to three tumor nodules (each less than 3 cm
in diameter) located in the periphery of the liver are considered(B) (C)
(F)
(H) (I)
(E)
th right lobe HCC focal lesion measuring about 5 cm in diameter
asic CT scan revealed faintly enhanced right lobe focal lesion in the
D and F) Post RFA triphasic CT scan obtained one month later
Follow-up triphasic CT scan obtained 6 months later revealed
428 M.A. Youssef et al.for percutaneous RFA under ultrasonographic, computed
tomography (CT) or magnetic resonance imaging guidance.
During the ablation process, conscious sedation or general
anesthesia is required because of pain associated with the heat-
ing of the liver capsule. The main advantage of this approach is
the possibility of early discharge of the patients after the
ablation procedure. It is associated with low morbidity and
mortality rates (15).
In our work, all of the RFA procedures were done through
percutaneous approach under ultrasonographic guidance.
Local anesthesia and conscious sedation were conducted for
all patients.
In our study, 67 of 100 (67%) were treated by Star burst XL
needle 5 CM (RITA system), 28 of 100 (28%) were treated by
LeVeen needle 4CM (Boston scientiﬁc system) and ﬁve of 100
patients (5%) were treated by Star burst XL needle 7 CM
(RITA system).
The most reported side effects of post ablation therapy were
pain, fever and asymptomatic right sided pleural effusion. Pain
and fever are attributed to the amount of tissue necrosis, while
the pleural effusions are more prominent while attempting
approaches to tumors located high along the dome of the dia-
phragm. Ground pad skin burns were also reported in 0.2% of
cases (16).
In our study, there were no fatal complications related to
RFA treatment. Nearly all the patients experienced post-
ablation right hypochondrial pain that was controlled by
analgesics, and nausea, which was controlled by antiemetic.
Also, nearly all experienced post-ablation pyrexia for 1–3 days,
which was controlled by antipyretics. This agrees with Mulier
et al. 2002 (17) who reported that 93% of HCC patients in his
study experienced post-ablation right hypochondrial pain.
In our study, 27 of 100 patients (27%) developed post RFA
complications. Twenty of 27 patients (74%) developed mild Rt
sided pleural effusion due to ablation of Sub-diaphragmatic
tumor, one of 27 patients (4%) developed peritoneal deposits,(A)
(D)
Fig. 2 Male patient 50 years old of Child-Pugh class A, presented
Combined therapy (single session of RFA and TACE was done). Tri
completely ablated (A–C). The patient was followed up for 12 months
at 6 month follow-up that was managed by TACE with hyperdense lip
adequate ablation (D–F).one of 27 patients (4%) developed mild peritoneal hemor-
rhage, 3 of 27 patients (11%) developed liver abscess and 2
of 27 patients (7%) developed post RFA treatment biliary
stricture, one of them was treated by external biliary drainage
and the other was treated by biliary stenting.
In our study, technical success (based on the absence of
residual or recurrent tumor at follow-up spiral triphasic CT)
was achieved in 92 of 100 (92%) patients treated by RFA after
the ﬁrst session, incomplete necrosis found in 8 of 100 patients
(8%).
In 3 of 8 patients (37.5%) incomplete ablation was due to
the site of the focal lesions as they were at the dome of the liver
(segment VIII) and one of 8 patients (12.5%) the focal lesion
was near a hepatic vein (heat sink phenomenon).
This is in agreement with Livragi et al. (18) and Solbiati
et al. (19) who have suggested that hepatic lesions in close
proximity to hepatic capsule, gall bladder and major blood
vessels either should not or could not be treated successfully.
In 4 of 8 (50%) patients incomplete ablation was due to
technical problem. In 7 of 8 patients (87.5%), second session
was done and complete ablation after the second session was
achieved. One of 8 patients (12.5%) with incomplete ablation
was treated by TACE as it was near a hepatic vein (heat sink
phenomenon). So success rate in achieving complete necrosis
after the ﬁrst session was (92%) which was in agreement with
Rossi et al. (20), Levragi et al. (21) and Curley et al. (22) who
reported a success rate of 91.7%, 90% and 96% respectively
and it was (99%) after the second session.
New HCCs developed after RFA were classiﬁed into recur-
rence of HCC in the same subsegment of the liver that previ-
ously was successfully ablated by RFA, and new HCCs
developed elsewhere in the liver segments. The former was
called local tumor progression (LTP) whereas the latter called
intrahepatic distant recurrence (IDR) based on standardiza-
tion of terminology and reporting criteria by the international
working group of image-guided tumor ablation (23).(B) (C)
(E) (F)
with LEFT lobe (III) HCC measuring about 2 cm in diameter.
phasic CT scan was done 1 month after RFA and the lesion was
with an evidence of local peritumoral recurrence could be detected
idol retention and no contrast enhancement at any phase indicates
(A) (B) (C)
(E)(D) (F)( )
Fig. 3 Male patient 60 years old of Child-Pugh class B, presented with right lobe (VII) HCC measuring about 2 cm in diameter enhanced
in the arterial phase and washout in the portovenous and delayed phases (A–C). Single session of RFA was done. Triphasic CT scan was
done 1 month after RFA and the lesion was completely ablated. The patient was followed up for 6 months with an evidence of a distant
recurrence could be detected at 3 month follow-up at area (IV) and a second session of RFA was done. Then at 6 month follow-up another
distant recurrence could be detected at area (III) and a session of alcohol injection was done (D–F).
Table 6 The mean survival (M) of 100 HCC patients in relation to Child-Pugh classiﬁcation, tumor number and tumor size.
Child classiﬁcation Number of the lesions Size of the lesions (cm)
A B C Single Multiple 63 cm >3–4 cm >4–5 cm
Mean survival (M) 21.8 ± 5.29 20.6 ± 5.399 12 ± 0.00 20.7 ± 5.414 19.2 ± 6.195 22 ± 4.560 20.5 ± 5.48 15.4 ± 5.85
P-value 0.021* 0.424 0.019*
* P< 0.05.
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occurred in 36 of 100 patients (36%). Local recurrence
occurred after one month in one of 36 patients (2.8%), after
3 months in 24 of 36 patients (66.7%), after 6 months in 8 of
36 patients (22.2%), after 9 months in 2 of 36 patients
(5.5%) and after 12 months in one of 36 patients (2.8%).
Eleven of 36 patients (30.5%) were treated by RFA, 24 of 36
patients (66.7%) were treated by TACE and one of 36 patients
(2.8%) was treated by alcoholic injection.
Local recurrence at RFA site is not frequent and its inci-
dence ranges from 5.7% to 39%. The local recurrence of
RFA might be attributed to several factors including tumor
characteristics and RFA techniques. Large tumor size (more
than 4 cm) is the main determining factor of local recurrence.
This matching with our study in whichmost of local recurrences
occurred in patients had focal lesions between 4 and 5 cm (24).
At the end of our study, the overall survival of the patients
was as following: 71 of 100 patients (71%) were alive and 29 of
100 patients (29%) were dead.
At the end of the ﬁrst year, the survival of the patients was
as following: 97 of 100 patients (97%) were alive and 3 of 100
patients (3%) were dead.
At the end of the second year, the survival of the patients
was as following: 71 of 97 patients were alive and 26 of 97
patients were dead.Lencioni et al. (25) reported the results of RFA in 206
patients with HCC in a mean follow-up of 24 months .the
survival rates were 97% at one year , 71% at 3 years and
48% at 5 years .Survival was signiﬁcantly greater in Child-
Pugh class A than child B class and in those with single tumors
compared with multiple tumors. This is in close agreement
with our results in which, the survival of the patients depends
on the severity of the liver cirrhosis, so the mean survival of
Child-Pugh Class A patients was 21.8 ± 5.29.8 m, for Child-
Pugh Class B patients was 20.6 ± 5.399 and for Child-Pugh
Class C patients was 12 ± 0.00.
The survival of the patients in relation to tumor number
was 20.7 ± 5.414 m for solitary tumors and 19.2 ± 6.195 for
multiple tumors. So, the tumor number has no signiﬁcant cor-
relation with the survival. The survival of the patients in rela-
tion to tumor size was 22 ± 4.560 m for tumors less than or
equal to 3 cm, 20.5 ± 5.48 for tumors 3.1–4 cm, and
15.4 ± 5.85 for tumors 4.1–5 cm. So, the tumor size has a
signiﬁcant correlation with the survival.
In conclusion, radiofrequency thermal ablation is a simple,
effective and less expensive technique with a low morbidity
compared with surgical treatment. Radiofrequency thermal
ablation can produce signiﬁcant long-term survival rates and
excellent local control for cirrhotic patients with early stage,
unresectable HCC.
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